Cell-Penetrating Peptide-Armed Antibody Fragment Delivers Doxorubicin to p16-High Cancers | Research

The takeaway

A scFv-CPP antibody fragment drug conjugate (AFDC) selectively killed p16-high cancer cells (HeLa, BT-549) and reduced viability in TNBC organoids through target-dependent internalization of doxorubicin.

Intracellular targeting
Cell-penetrating peptide enables antibody fragment to reach and target the intracellular protein p16 — previously undruggable by antibody approaches

What the researchers found

scFv-p16-S413-doxorubicin AFDC: p16 expression-dependent selectivity, stronger cytotoxicity against p16-high (HeLa, BT-549) vs p16-low cells, target-dependent internalization, and marked viability reduction in TNBC organoids.

Why it matters

p16 is overexpressed in many aggressive cancers but has been undruggable. AFDCs combining antibody targeting with cell-penetrating peptides could unlock many intracellular cancer targets.

How the study worked

scFv isolation from hybridomas, humanization, CPP S413 fusion, doxorubicin conjugation, binding/internalization assays, selective cytotoxicity in p16-high/low cells, and TNBC organoid models.

What this study cannot tell us

In vitro proof-of-concept. In vivo efficacy and toxicity not tested. Manufacturing complexity of the multi-component conjugate.

How to read the evidence

Proof-of-concept in vitro study with cell line and organoid validation. Novel platform demonstrating feasibility.

When this study was published

Published in 2025.

The bigger picture

The AFDC platform extends drug conjugate technology from cell-surface targets to intracellular proteins, potentially unlocking a vast category of cancer targets.

Questions still open

Would AFDC show tumor-selective killing in animal models?
Can the platform target other intracellular oncoproteins?
How does AFDC pharmacokinetics compare to conventional ADCs?

Common questions

How can you target a protein inside cancer cells?

By fusing a cancer-targeting antibody fragment with a cell-penetrating peptide (S413) that punches through cell membranes. This carries the attached drug (doxorubicin) directly inside cancer cells.

What is p16 and why target it?

p16 is a protein overexpressed in many aggressive cancers. It has been impossible to target with regular antibodies because it is inside cells. This CPP-armed antibody fragment solves that problem.

Read the original research

Development and In vitro antitumor evaluation of a novel anti-p16 antibody fragment-drug conjugate.

International immunopharmacology, 174, 116359

View on PubMed ↗Publisher’s paper ↗

Citation

He, Hui; Chen, Xiaoling; Chen, Yueqiu; Li, Qingpeng; Yang, Fan; Zhou, Lin. (2026). Development and In vitro antitumor evaluation of a novel anti-p16 antibody fragment-drug conjugate.. International immunopharmacology, 174, 116359. https://doi.org/10.1016/j.intimp.2026.116359